ETON News and Press, Eton Pharmaceutcials Inc. From 08/07/25

Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18 th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million Launched KHINDI...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

Eton Pharmaceuticals Inc. (ETON) is expected to report $0 for Q2 2025

DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report secon...

2025-07-23 10:48:22 ET Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 2.54% on the day to $14.96. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commerci...

2025-07-18 11:41:00 ET Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 8.14% on the day to $15.09. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commerci...

2025-07-15 09:33:40 ET Eton Pharmaceuticals (NASDAQ: ETON ) operates in the tiny ultra-rare disease niche. I have previously written a deep dive on ETON's business model , in which I argued they are likely to dominate the "orphan drug" space, so for anyone interested in a full d...

2025-07-10 11:55:11 ET Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -0.06% on the day to $15.76. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commerc...

2025-07-08 07:33:09 ET More on Eton Pharmaceuticals Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside Eton Pharmaceuticals Set To Dominate Orphan Drug Niche Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript ...

- NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company f...